Regulation of Platelet Function by Nitric Oxide

Advances in Molecular and Cell Biology

Volumn 18, Issue C, 1997, Pages 367-381

  Radomski, Marek W ^a   Moncada, Salvador ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 42449116296     PISSN: 15692558     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1569-2558(08)60422-1     Document Type: Article

References (104)

1. Alheid U., Reichwehr I., and Forstermann U. Human endothelial cells inhibit platelet aggregation by separately stimulating platelet cyclic AMP and cyclic GMP. Eur. J. Pharmacol. 164 (1989) 103-110
2. Amado J.A., Salas E., Botana M.A., Poveda J.J., and Berrazueta J.R. Low levels of intraplatelet cGMP in 1DDM. Diabetes Care 16 (1993) 809-811
3. Aono J., Sugawa M., Koide T., and Takato M. The role of cGMP in the anti-aggregating properties of BY 1949, a novel dibenzoxazepine derivative. Eur. J. Pharmacol. 195 (1991) 225-231
4. Azuma H., Ishikawa M., and Sekizaki S. Endothelium-dependent inhibition of platelet aggregation. Br. J. Pharmacol. 88 (1986) 411-415
5. Barrett M.L., Willis A.L., and Vane J.R. Inhibition of platelet-derived mitogen release by nitric oxide (EDRF). Agents and Actions 27 (1989) 488-491
6. Beckman J.S., Beckman T.W., Chen J., Marshall P.A., and Freeman B.A. Apparent hydroxyl radical production by peroxynitrite: Implications for endothelial injury from nitric oxide and superoxide. Proc. Natl. Acad. Sci. USA 87 (1990) 1620-1624
7. Berkels R., Klaus W., and Rosen R. Nifedipine induced inhibition of platelet aggregation-a nitric oxide mediated process. Endothelium 1 (1993) S69
8. Bhardwaj R., Page C.P., May G.R., and Moore P.K. Endothelium-derived relaxing factor inhibits platelet aggregation in human whole blood in vitro and in the rat in vivo. Eur. J. Pharmacol. 157 (1988) 83-91
9. Bredt D.S., Hwang P.M., Glatt C.E., Lowenstein C., Reed R.R., and Snyder S.H. Cloned and expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase. Nature 351 (1991) 714-718
10. Broekman M.J., Eiroa A.M., and Marcus A.J. Inhibition of human platelet reactivity by endothelium-derived relaxing factor from human umbilical vein endothelial cells in suspension: Blockade of aggregation and secretion by an aspirin-insensitive mechanism. Blood 78 (1991) 1033-1040
11. Brune B., and Volker U. Different calcium pools in human platelets and their role in thromboxane A2 formation. J. Biol. Chem. 266 (1991) 19232-19237
12. Bult H., Fret H.R.L., van den Bossche R.M., and Herman A.G. Platelet inhibition by endothelium-derived relaxing factor from the rabbit perfused aorta. Br. J. Pharmacol. 95 (1988) 1308-1314
13. Bult H., Fret H.R.L., Jordaens F.H., and Herman A.G. Dipyridamole potentiates the antiaggregating and vasodilator activity of nitric oxide. Eur. J. Pharmacol. 199 (1991) 1-8
14. Busse R., Luckhoff A., and Bassenge E. Endothelium-derived relaxing factor inhibits platelet activation. Naunyn Schmiedeberg's Arch. Pharmacol. 336 (1987) 566-571
15. Cadwgan T.M., and Benjamin N. Evidence for altered platelet nitric oxide synthesis in essential hypertension. J. Hypert. 11 (1993) 417-420
16. Calver A., Collier J., Moncada S., and Vallance P. Effect of local infusion of NG-monomethylL-arginine in patients with hypertension. The nitric oxide dilator mechanism appears abnormal. J. Hypertens. 10 (1992) 1025-1031
17. Calver A., Collier J., and Vallance P. Inhibition and stimulation of nitric oxide synthesis in the human forearm arterial bed of patients with insulin-dependent diabetes. J. Clin. Invest. 90 (1992) 2548-2554
18. Chester A.H., O'Neil G.S., Moncada S., Tadjkarimi S., and Yacoub M. Low basal and stimulated release of nitric oxide in atherosclerotic epicardial coronary arteries. Lancet 336 (1990) 897-900
19. Cooke J.P., Rossitch Jr. E., Andon N.A., Loscalzo J., and Dzau V.J. Flow activates an endothelial potassium channel to release an endogenous nitrovasodilator. J. Clin. Invest. 88 (1991) 1663-1671
20. Cooke J.P., and Tsao P. Cellular mechanisms of atherogenesis and the effects of nitric oxide. Curr. Opin. Cardiol. 7 (1992) 799-804
21. Corrigan Jr. J.J., Ray W., and May N. Changes in the blood coagulation system associated with septicemia. New Eng. J. Med. 279 (1968) 851-856
22. Craeger M.A., Gallagher S.J., Girerd X.J., Coleman S.M., Dzau V.J., and Cooke J.P. L-Arginine improves endothelium-dependent vasodilatation in hypercholesterolemic humans. J. Clin. Invest. 90 (1992) 1248-1253
23. Craven P.A., and De Rubertis F.R. Restoration of the responsiveness of purified guanylate cyclase to nitrosoguanidine, nitric oxide, and related activators by heme and hemoproteins. Evidence for involvement of the paramagnetic nitrosyl-heme complex in enzyme activation. J. Biol. Chem. 253 (1978) 8433-8443
24. De Belder A., MacAllister R.A., Radomski M.W., Moncada S., and Vallance P. Effects of S-nitrosoglutathione in the circulation of human forearm. Cardiovasc. Res. 28 (1994) 691-694
25. De Graaf J.C., Banga J.D., Moncada S., Palmer R.M.J., de Groot P.G., and Sixma J.J. Nitric oxide functions as an inhibitor of platelet adhesion under flow conditions. Circulation 85 (1992) 2284-2290
26. Drexler H., Zeiher A.M., Meinzer K., and Just H. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine. Lancet 338 (1991) 1546-1550
27. Feelisch M., and Noack E.A. Correlation between nitric oxide formation during degradation of organic nitrates and activation of guanylate cyclase. Eur. J. Pharmacol. 139 (1987) 19-30
28. Furchgott R.F., and Zawadzki J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288 (1980) 373-376
29. Furlong B., Henderson A.H., Lewis M.J., and Smith J.A. Endothelium-derivedrelaxing factor inhibits in vitro platelet aggregation. Br. J. Pharmacol. 90 (1987) 687-692
30. Gebalska, J. (1990). Platelet adhesion and aggregation in relation to clinical course of acute myocardial infarction. M.D. thesis, Warsaw, in Polish.
31. Geiger J., Nolte C., Butt E., Sage S.O., and Walter U. Role of cGMP and cGMP-dependent protein kinase in nitrovasodilator inhibition of agonist-evoked calcium elevation in human platelets. Proc. Natl. Acad. Sci. USA 89 (1992) 1031-1035
32. Gerzer R., Karrenbrock B., Siess W., and Heim J.M. Direct comparison of the effects of nitroprusside, SIN 1, and various nitrates on platelet aggregation and soluble guanylate cyclase activity. Thromb. Res. 52 (1988) 11-21
33. Goldberg N.D., Haddox M.K., Nicol S.E., Glass D.B., Sanford C.H., Kuehl Jr. F.A., and Estensen R. In: Drummond G.I., Greengard P., and Robinson G.A. (Eds). Advances in Cyclic Nucleotide Research 5 (1975), Raven Press, New York
34. Golino P., Capelli-Bigazzi M., Ambrosio G., Ragni M., Russolillo E., Condorelli M., and Chiariello M. Endothelium-derived relaxing factor modulates platelet aggregation in an in vivo model of recurrent platelet activation. Circ. Res. 71 (1992) 1447-1456
35. Gryglewski R.J., Palmer R.M.J., and Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 320 (1986) 454-456
36. Hawkins D.J., Meyri B.O., and Murray J.J. Activation of guanylate cyclase and inhibition of platelet aggregation by endothelium-derived relaxing factor released from cultured cells. Biochim. Biophys. Acta 969 (1988) 289-296
37. Herbaczynska-Cedro K., Lembowicz K., and Pytel B. NG-monomethyl-L-arginine increases platelet deposition on damaged endothelium in vivo. A scanning electron microscopy study. Thromb. Res. 64 (1991) 1-9
38. Hibbs Jr. J.B., Taintor R.R., Vavrin Z., Granger D.L., Drapier J.C., Amber I.J.L., and Lancaster Jr. J.R. Synthesis of nitric oxide from a terminal guanidino nitrogen atom of L-arginine: A molecular mechanism regulating cellular proliferation that targets intracellular iron. In: Moncada S., and Higgs E.A. (Eds). Nitric Oxide from L-Arginine: A Bioregulatory System (1990), Elsevier, Amsterdam 189-233
39. Hogan J.C., Lewis M.J., and Henderson A.H. In vivo EDRF activity influences platelet function. Br. J. Pharmacol. 94 (1988) 1020-1022
40. Houston D.S., Robinson P., and Gerrard J.M. Inhibition of intravascular platelet aggregation by endothelium-derived relaxing factor: Reversal by red blood cells. Blood 76 (1990) 953-958
41. Humphries R.G., Tomlinson W., O'Connor S.E., and Leff P. Inhibition of collagen-and ADP-induced platelet aggregation by substance P in vivo: Involvement of endothelium-derived relaxing factor. J. Cardiovasc. Pharmacol. 16 (1990) 292-297
42. Hunt N.C.A., and Goldin R.D. Nitric oxide production by monocytes in alcoholic liver disease. J.Hepatol. 14 (1992) 146-150
43. Ialenti A., Moncada S., and Di Rosa M. Modulation of adjuvant arthritis by endogenous nitric oxide. Br. J. Pharmacol. 110 (1993) 701-706
44. Ivanova K., Schaefer M., Drummer C., and Gerzer R. Effects of nitric oxide-containing compounds on increases in cytosolic ionized calcium and on aggregation of human platelets. Eur. J. Pharmacol. 244 (1993) 37-47
45. Kilbourn R.G., Gross S.S., Adams J., Jubran A., Griffith O.W., Levi R., and Lodato R.F. N-methyl-L-arginine inhabits tumor necrosis factor-induced hypotension: implications for the involvement of nitric oxide. Proc. Natl. Acad. Sci. USA 87 (1990) 3629-3632
46. Kubes P., Suzuki M., and Granger D.N. Nitric oxide: An endogenous modulator of leukocyte adhesion. Proc. Natl. Acad. Sci. USA 88 (1991) 4651-4655
47. Kurose I., Kubes P., Wolf R., Anderson D.C., Paulson J., Miyasaka M., and Granger D.N. Inhibition of nitric oxide production. Mechanisms of vascular albumin leakage. Circ. Res. 73 (1993) 164-171
48. Lelchuk R., Radomski M.W., Martin J.E., and Moncada S. Constitutive and inducible nitric oxide synthases in human megakaryoblastic cells. J. Pharmacol. Exp. Ther. 262 (1992) 1220-1224
49. Lyons C.R., Orloff G.J., and Cunningham J.M. Molecular cloning and functional expression of an inducible nitric oxide synthase from a murine macrophage cell line. J. Biol. Chem. 267 (1992) 6470-6474
50. Macdonald P.S., Read M.A., and Dusting G.J. Synergistic inhibition of platelet aggregation by endothelium-derived relaxing factor and prostacyclin. Thromb. Res. 49 (1988) 437-449
51. Malinski T., Radomski M.W., Taha Z., and Moncada S. Direct electrochemical measurement of nitric oxide released from human platelets. Biochem. Biophys. Res. Commun. 194 (1993) 960-965
52. Marcus A.J., and Zucker M.B. 77ie Physiology of Blood Platelets (1965), Grune & Stratton Inc., New York, London
53. Marsden P.A., Shappert K.T., Chen H.S., Flowers M., Sundell C.L., Wilcox J.N., Lamas S., and Michel T. Molecular cloning and characterisation of human endothelial nitric oxide synthase. FEBS Lett. 307 (1992) 287-293
54. Maurice D.H., and Haslam R.J. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: Inhibition of cyclic AMP breakdown by cyclic GMP. Mol. Pharmacol. 37 (1990) 671-681
55. May G.R., Crook P., Moore P.K., and Page C.P. The role of nitric oxide as an endogenous regulator of platelet and neutrophil activation within the pulmonary circulation. Br. J. Pharmacol. 102 (1991) 759-763
56. McCall T.B., Boughton-Smith N.K., Palmer R.M.J., Whittle B.J.R., and Moncada S. Synthesis of nitric oxide from L-arginine by neutrophils. Biochem. J. 261 (1989) 293-296
57. Mehta J.L., and Chen L.Y. J. Lab. Clin. Med. 125 (1995) 370-377
58. Mellion B.T., Ignarro L.J., Myers C.B., Ohlstein E.H., Ballot B.A., Hyman A.L., and Kadowitz P.J. Inhibition of human platelet aggregation by S-nitrosothiols. Heme-dependent activation of soluble guanylate cyclase and stimulation of cyclic GMP accumulation. Mol. Pharmacol. 23 (1983) 653-664
59. Mellion B.T., Ignarro L.J., Ohlstein E.H., Pontecorvo E.G., Hyman A.L., and Kadowitz P.J. Evidence for the inhibitory role of guanosine 3′, 5′-monophosphate in ADP-induced human platelet aggregation in the presence of nitric oxide and related vasodilators. Blood 57 (1981) 946-955
60. Moilanen E., Vuorinen P., Metsa-Ketela T., and Vapaatalo H. Inhibition by nitric oxide donors of human polymorphonuclear leucocyte functions. Br. J. Pharmacol. 109 (1993) 852-858
61. Molina y Vedia L., Mc Donald B., Reep B., Brune B., Di Silvio M., Billiar T.R., and Lapetina E.G. Nitric oxide-induced S-nitrosylation of glyceraldehyde-3-phosphate dehydrogenase inhibits enzymatic activity and increases endogenous ADP-ribosylation. J. Biol. Chem. 257 (1992) 24929-24932
62. Moncada S. The 1991 Ulf von Euler Lecture. The L-Arginine: Nitric oxide pathway. Acta Physiol. Scand. 145 (1992) 201-227
63. Moncada S., Gryglewski R.J., Bunting S., and Vane J.R. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 263 (1976) 663-665
64. Moncada S., and Higgs E.A. The L-Arginine-nitric oxide pathway. New Eng. J. Med. 329 (1993) 2002-2012
65. Morgan R.O., and Newby A.C. Nitroprusside differentially inhibits ADP-stimulated calcium influx and mobilization in human platelets. Biochem. J. 258 (1989) 447-454
66. Moro M.A., Salas E., Radomski M.W., Askew S., Hodson H.H., Butler A.R., and Moncada S. Comparative pharmacology of analogues of S-nitroso-N-acetyl-DL-penicillamine in platelets. Endothelium 1 (1993) S39
67. Muruganandam A., and Mutus B. Biochim. Biophys. Acta 1200 (1994) 1-6
68. Nakashima S., Tohmatsu T., Hattori H., Okano Y., and Nozawa Y. Inhibitory action of cyclic GMP on secretion, phosphoinositide hydrolysis and calcium mobilization in thrombin-stimulated human platelets. Biochem. Biophys. Res. Commun. 135 (1986) 1099-1104
69. Noris M., Benigni A., Boccardo P., Aiello S., Gaspari F., Todeschini M., Figliuzzi M., and Remuzzi G. Enhanced nitric oxide synthesis in uremia: Implications for platelet dysfunction and dialysis hypotension. Kidney Int. 44 (1993) 445-450
70. Palmer R.M.J., Ashton D.S., and Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 333 (1988) 664-666
71. Palmer R.M.J., Bridge L., Foxwell N.A., and Moncada S. The role of nitric oxide in endothelial cell damage and its inhibition by glucocorticoids. Br. J. Pharmacol. 105 (1992) 11-12
72. Palmer R.M.J., Ferrige A.G., and Moncada S. Nitric oxide accounts for the biological activity of endothelium-derived relaxing factor. Nature 327 (1987) 524-526
73. Palmer R.M.J., Rees D.D., Ashton D.S., and Moncada S. L-Arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation. Biochem. Biophys. Res. Commun. 153 (1988) 1251-1256
74. Petros A., Bennet D., and Vallance P. Effect of NO synthase inhibitors on hypotension in patients with septic shock. Lancet 338 (1991) 1557-1558
75. Pohl U., and Busse R. EDRF increases cyclic GMP in platelets during passage through the coronary vascular bed. Circ. Res. 65 (1989) 1798-1803
76. Pronai L., Ichimori K., Nozaki H., Nakazawa H., Okino H., Carmichael A.J., and Arroyo C.M. Investigation of the existence and biological role of L-arginine/nitric oxide pathway in human platelets by spin-trapping/EPR studies. Eur. J. Biochem. 202 (1991) 923-930
77. Radomski M.W., Palmer R.M.J., and Moncada S. Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets. Br. J. Pharmacol. 92 (1987) 181-187
78. Radomski M.W., Palmer R.M.J., and Moncada S. The anti-aggregating properties of vascular endothelium: Interactions between prostacyclin and nitric oxide. Br. J. Pharmacol. 92 (1987) 639-646
79. Radomski M.W., Palmer R.M.J., and Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 2 (1987) 1057-1058
80. Radomski M.W., Palmer R.M.J., and Moncada S. The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochem. Biophys. Res. Commun. 148 (1987) 1482-1489
81. Radomski M.W., Palmer R.M.J., and Moncada S. An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc. Natl. Acad. Sci. USA 87 (1990) 5193-5197
82. Radomski M.W., Palmer R.M.J., and Moncada S. Characterization of the L-arginine: Nitric oxide pathway in human platelets. Br. J. Pharmacol. 101 (1990) 325-328
83. Radomski M.W., Palmer R.M.J., and Moncada S. Glucocorticoids inhibit the expression of an inducible but not the constitutive nitric oxide synthase in vascular endothelial cells. Proc. Natl. Acad. Sci. USA 87 (1990) 10043-10047
84. Radomski M.W., Rees D.D., Dutra A., and Moncada S. S-nitrosoglutathione inhibits platelet activation in vitro and in vivo. Br. J. Pharmacol. 107 (1992) 745-749
85. Radomski M.W., Vallance P., Whitley G., Foxwell N., and Moncada S. Platelet adhesion to human vascular endothelium is modulated by constitutive and cytokine induced nitric oxide. Cariovasc. Res. 27 (1993) 1380-1382
86. Rees D.D., Cellek S., Palmer R.M.J., and Moncada S. Dexamethasone prevents the induction by endotoxin of a nitric oxide synthase and the associated effects on vascular tone: An insight into endotoxin shock. Biochem. Biophys. Res. Commun. 173 (1990) 541-547
87. Rees D.D., Palmer R.M.J., and Moncada S. Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc. Natl. Acad. Sci. USA 86 (1989) 3375-3378
88. Rosenblum W.I., Nelson G.H., and Povlishock J.T. Laser-induced endothelial damage inhibits endothelium-dependent relaxation in the cerebral microcirculation of the mouse. Circ. Res. 60 (1987) 169-176
89. Sase K., and Michel T. Life Sci. 22 (1995) 2049-2055
90. Schultz P.J., and Raij L. Endogenously synthesized nitric oxide prevents-endotoxin-induced glomerular thrombosis. J. Clin. Invest. 90 (1992) 1718-1725
91. Scott-Burden T., and Vanhoutte P.M. Regulation of vascular smooth muscle proliferation: Role of endothelium-derived relaxing factor (nitric oxide). J. Vase. Biol. 3 (1991) 445-446
92. Sessa W.V., Harrison J.K., Barber C.M., Zeng D., Durieux M.E., D'Angelo D.D., Lynch K.R., and Peach M.J. Molecular cloning and expression of cDNA encoding endothelial cell nitric oxide synthase. J. Biol. Chem. 267 (1992) 15274-15276
93. Sinzinger H., Fitscha P., O'Grady J., Rauscha F., Rogatti W., and Vane J.R. Synergistic effect of prostaglandin E, and isosorbide dinitrate in peripheral vascular disease. Lancet 335 (1990) 627-628
94. Sinzinger H., Rauscha E., O'Grady J., and Fitscha P. Prostaglandin I2 and the nitric oxide donor molsidomine have synergistic effects on thromboresistance in man. Br. J. Clin. Pharmacol. 33 (1992) 289-292
95. Sinzinger H., Virgolini I.O., Grady J., Rauscha F., and Fitscha P. Modification of platelet function by isosorbide dinitrate in patients with coronary artery disease. Thromb. Res. 65 (1992) 323-335
96. Sneddon J.M., and Vane J.R. Endothelium-derived relaxing factor reduces platelet adhesion to bovine endothelial cells. Proc. Natl. Acad. Sci. USA 85 (1988) 2800-2804
97. Stamler J.S., Jaraki O., Osborne J., Simon D.I., Keaney J., Vita J., Singel D., Valeri C.R., and Loscalzo J. Nitric oxide circulates in mammalian plasma primarily as an S-nitroso adduct of serum albumin. Proc. Natl. Acad. Sci. USA 89 (1992) 7674-7677
98. Stamler J.S., Vaughan D.E., and Loscalzo J. Synergistic disaggregation of platelets by tissue-type plasminogen activator, prostaglandin Ej and glyceryl trinitrate. Circ. Res. 65 (1989) 796-804
99. Venturini C.M., Del Vecchio P.J., and Kaplan J.E. Thrombin-induced platelet adhesion to endothelium is modified by endothelial derived relaxing factor (EDRF). Biochem. Biophys. Res. Commun. 159 (1989) 349-354
100. Venturini C.M., Weston L.K., and Kaplan J.E. Platelet cGMP but not cAMP, inhibits thrombin-induced platelet adhesion to pulmonary vascular endothelium. Am. J. Physiol. 32 (1992) H606-H612
101. Verbeuren T.J., Jordaens F.H., Zonnekeyn L.L., van Hove C.E., Coene M.C., and Herman A.G. Effect of hypercholesterolemia on vascular reactivity in the rabbit. I. Endothelium dependent and endothelium-independent contractions and relaxations in isolated arteries of control and hypercholesterolemic rabbits. Circ. Res. 58 (1986) 552-564
102. Walter U. Physiological role of cGMP and cGMP-dependent protein kinase in the cardiovascular system. Rev. Physiol. Biochem. Pharmacol. 113 (1989) 41-88
103. Wautier J.L., Weill D., Kadeva H., Maclouf J., and Soria C. Modulation of platelet function by SIN-1A. J. Cardiovasc. Pharmacol. 14 (1989) S111-S114
104. Yao S.K., Ober J.C., Krishnaswami A., Ferguson J.J., Anderson H.V., Golino P., Buja L.M., and Willerson J.T. Endogenous nitric oxide protects against platelet aggregation and cyclic flow variations in stenosed and endothelium-iniured arteries. Circulation 86 (1992) 1302-1309